Pharmabiotech Stocks To Watch This Prostate Cancer Month | Latest News RSS feed

Pharmabiotech Stocks To Watch This Prostate Cancer Month - Latest News

Pharma/Biotech Stocks to Watch This Prostate Cancer Month

September is observed as National Prostate Cancer Month to raise awareness about the disease, which is the leading cause of death in men, second only to skin cancer in the United States. A light blue ... read more

10 Pharma Stocks To Watch This Month

Watch out for... A phase III study of 1404, a PSMA-targeted small molecule SPECT/CT imaging agent in patients with newly-diagnosed or low-grade prostate cancer, dubbed ProSPECT-AS, is underway. ... read more

This Week June 20-24: Breakout Stocks to Watch and 1 Speculative Biotech

I like the long-term growth prospects of PSMT and technicals; however, my long position was not initiated until over a month after it appeared on my "Stocks to Watch This Week ... cancers such as lung ... read more

Looking for another news?

Biopharma Companies to Watch This Week

But with the risk of failure, which could spell disaster for a stock, comes great reward as well ... PSMA-617 is a radioligand therapy for the targeted treatment of prostate cancer. Shares of Endocyte ... read more

Stocks to watch Friday: TI, Dendreon, Tessera

WASHINGTON (MarketWatch) — Among the stocks that could see active trade in Friday ... the biotech company’s new therapy for treating prostate cancer. The cuts, concentrated among manufacturing workers ... read more

Cancer Stocks on Tap: ASCO Abstract Preview

May 18, the American Society of Clinical Oncology (ASCO) will be posting online the full content of cancer drug research abstracts to be presented next month at its closely ... Biotech traders start ... read more

Today’s Research Reports on Stocks to Watch: AbbVie and Progenics Pharmaceuticals

It is being studied as a once-daily therapy in atopic dermatitis and the Phase 3 clinical program was initiated last month. According to the results ... the phase 3 clinical trial testing of its ... read more

Clovis Oncology stock rises 10% after 'breakthrough' designation from FDA

The designation could expedite the development and review of Rubraca by the FDA for BRCA1/2-mutated metastatic castration-resistant prostate ... last month on charges of misleading investors about the ... read more

9 Pharma Stocks To Watch This Month

(RTTNews) - Biotech stocks ... cancer and prostate cancer. Watch out for… Interim safety and efficacy data from Stage 1 of the phase II clinical trial of SM-88 in metastatic pancreatic cancer, dubbed ... read more

FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us